IDT v. Pillar Biosciences: Federal Circuit Affirms Multiplex PCR Patent Unpatentable
Integrated DNA Technologies challenged the validity of US10316359B2, a patent covering methods for multiplex PCR held by Pillar Biosciences. The Federal Circuit affirmed the finding of unpatentability after an 841-day appellate proceeding, leaving the patent cancelled and Pillar’s IP position in molecular diagnostics significantly weakened.
Federal Circuit seals multiplex PCR patent cancellation after two-year appeal
Integrated DNA Technologies, Inc. (IDT), a leading molecular biology reagent and oligonucleotide company, brought an invalidity/cancellation action targeting US10316359B2, a patent held by Pillar Biosciences, Inc. covering methods for multiplex PCR — a foundational technique in clinical genomics and molecular diagnostics. The case was appealed to the Court of Appeals for the Federal Circuit under case number 22-2172, filed on 1 September 2022.
The Federal Circuit issued an affirmance on 20 December 2024, upholding the determination that the patent claims of US10316359B2 are unpatentable. An affirmance at the appellate level means the court found no reversible legal or factual error in the lower tribunal’s invalidity finding, making the cancellation final subject only to a petition for certiorari to the Supreme Court. For Pillar Biosciences, the patent is effectively eliminated as an enforceable asset.
The 841-day duration from filing to disposition is consistent with substantively contested Federal Circuit appeals in the biotechnology patentability space, where claim construction and prior art analysis can be complex. The public record does not disclose the specific prior art grounds underpinning unpatentability, nor whether a rehearing petition was filed. What is clear is that IDT achieved its objective of clearing this multiplex PCR patent from the competitive landscape.
Filing to Unpatentable in 841 days
841 days — above the Federal Circuit median for patent validity appeals
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the invalidity finding is now final
When the Federal Circuit affirms, it concludes that the tribunal below committed no reversible error in law or fact. In a patentability/invalidity action, affirmance means the challenged claims are cancelled and cannot be resurrected in the same proceeding. The patent holder’s only remaining avenue is a petition for certiorari to the U.S. Supreme Court, which is granted in a very small minority of patent cases.
Invalidity upheld on appealPillar Biosciences loses its multiplex PCR patent protection
For Pillar Biosciences, the Federal Circuit’s affirmance is a definitive adverse outcome. US10316359B2 is no longer enforceable, removing a potential barrier to competitor entry in the multiplex PCR diagnostics space. Any licensing revenue stream tied to this patent is extinguished, and Pillar cannot assert these specific claims against future infringers. The company’s IP portfolio in molecular diagnostics is materially narrowed by this result.
Patent cancelled — unenforceableIDT clears a competitive IP barrier in multiplex PCR
Integrated DNA Technologies successfully invalidated a patent that could have been asserted against its multiplex PCR products or services. The affirmance at the Federal Circuit level — the apex court for U.S. patent matters — provides IDT with a high-confidence freedom-to-operate in the method space covered by the now-cancelled claims. This outcome also signals IDT’s willingness to pursue and sustain multi-year appellate litigation to protect its genomics product lines.
FTO strengthened for IDTMultiplex PCR method space opens further for competitors
The cancellation of US10316359B2 reduces patent thicket risk in multiplex PCR workflows, a method widely deployed in oncology panels, infectious disease diagnostics, and liquid biopsy. Companies developing or commercialising multiplex PCR kits and assays may benefit from the cleared IP landscape. However, Pillar Biosciences likely holds other IP assets, and practitioners should conduct a full portfolio review before drawing broad FTO conclusions from this single cancellation.
Reduced PCR patent thicket riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | INTEGRATED DNA TECHNOLOGIES, INC. | Company | Molecular biology reagents and genomics tools company — challenger of US10316359B2Search in Eureka ↗ |
| Defendant | Pillar Biosciences, Inc. | Company | Pillar Biosciences, Inc. — molecular diagnostics company, holder of US10316359B2Search in Eureka ↗ |
| Plaintiff counsel | Mark Christopher Nelson | Attorney | Counsel for INTEGRATED DNA TECHNOLOGIES, INC.Search in Eureka ↗ |
| Plaintiff counsel | Matthew S. Gibson | Attorney | Counsel for INTEGRATED DNA TECHNOLOGIES, INC.Search in Eureka ↗ |
| Plaintiff counsel | Ronald E. Cahill | Attorney | Counsel for INTEGRATED DNA TECHNOLOGIES, INC.Search in Eureka ↗ |
| Plaintiff counsel | Steven Shipe | Attorney | Counsel for INTEGRATED DNA TECHNOLOGIES, INC.Search in Eureka ↗ |
| Plaintiff law firm | Barnes & Thornburg, LLP | Law Firm | Representing INTEGRATED DNA TECHNOLOGIES, INC.Search in Eureka ↗ |
| Defendant counsel | Brian Robert Matsui | Attorney | Counsel for Pillar Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Jian Xiao | Attorney | Counsel for Pillar Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew Ian Kreeger | Attorney | Counsel for Pillar Biosciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Morrison & Foerster, LLP | Law Firm | Representing Pillar Biosciences, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The single-word verdict — AFFIRMED — reflects the Federal Circuit’s conclusion that the invalidity/cancellation determination below was legally and factually sound. At the appellate level, the court reviews claim construction de novo and factual findings underlying patentability (such as prior art, obviousness, and written description) under a substantial evidence standard. An unqualified affirmance, without remand, indicates the panel found the unpatentability grounds fully supported and no claim survived challenge. For Pillar Biosciences, this forecloses further argument on the merits of US10316359B2 at the appellate tier.
US10316359B2 — Methods for Multiplex PCR in Molecular Diagnostics
US10316359B2 (application number US15/252397) covers methods for multiplex PCR — a technique enabling simultaneous amplification of multiple DNA targets in a single reaction. Multiplex PCR is foundational to oncology genomic panels, infectious disease diagnostics, pharmacogenomics, and liquid biopsy workflows. The patent was held by Pillar Biosciences, a company focused on targeted next-generation sequencing panels for clinical oncology, making its claims directly relevant to commercially active diagnostic product lines.
From a competitive standpoint, a method patent covering multiplex PCR workflows represents a potential gating asset in a high-growth diagnostics segment. IDT, as a dominant supplier of oligonucleotides and PCR reagents, had strong commercial incentive to challenge and cancel such claims. The Federal Circuit’s affirmance of unpatentability suggests the claims lacked sufficient novelty or non-obviousness over the prior art, which is consistent with the long-established scientific literature on multiplex amplification strategies. Companies building PCR-based diagnostic platforms should assess the prior art basis for the cancellation when evaluating their own claim portfolios.
Should you run an FTO analysis referencing US10316359B2?
Product and R&D teams developing multiplex PCR assays, NGS library preparation kits, or clinical genomic panels should be aware that US10316359B2 has been cancelled following Federal Circuit affirmance. However, freedom-to-operate in the multiplex PCR space cannot rest on this cancellation alone. Pillar Biosciences may hold continuation patents, divisional applications, or related family members that survived this proceeding and cover overlapping method claims. Any team commercialising PCR multiplexing workflows should conduct a full family-level FTO review.
PatSnap Eureka’s FTO Search Agent can map the full patent family surrounding US10316359B2, identify surviving related applications from Pillar Biosciences and other diagnostics players, and flag claim overlap with your specific multiplex PCR workflow steps. Eureka can also surface Federal Circuit appeal histories for related patents, helping IP counsel and R&D leaders prioritise which remaining claims merit formal FTO opinions before product launch or partnership due diligence.
Run a freedom-to-operate analysis on US10316359B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit Patent Validity Appeals in Molecular Diagnostics
Related Federal Circuit appeals involving multiplex PCR, genomics method patents, and invalidity affirmances in molecular diagnostics and genomics tools.
What this case signals for the molecular diagnostics IP landscape
A Federal Circuit affirmance of unpatentability in multiplex PCR raises the stakes for method claim drafting across genomics tools and diagnostics.
Multiplex PCR method claims face elevated invalidity scrutiny at the Federal Circuit
This outcome suggests that broadly drafted method claims in multiplex PCR workflows are vulnerable to invalidity challenges, particularly when asserted against well-resourced genomics tools companies like IDT. IP teams protecting PCR-based diagnostics should audit claim specificity and ensure robust prior art differentiation before enforcement or licensing discussions.
IDT’s willingness to sustain 841-day appeals is a deterrent signal to competitors
The duration and appellate level of this litigation demonstrates that IDT invests significantly in clearing IP barriers to its core product lines. Competitors and patent holders in the oligonucleotide and genomics reagent space should factor IDT’s litigation profile into IP strategy, particularly when considering whether to assert method patents against IDT’s multiplex PCR offerings.
INTEGRATED v Pillar — key questions answered
The Federal Circuit affirmed the unpatentability of US10316359B2, covering methods for multiplex PCR. The court found no reversible error in the lower tribunal’s invalidity/cancellation finding. The decision, issued on 20 December 2024, effectively cancels the patent and forecloses further merits appeal at the Federal Circuit level.
US10316359B2 (application US15/252397) covers methods for multiplex PCR — simultaneous amplification of multiple DNA targets. Pillar Biosciences held the patent for use in clinical oncology genomic panels. IDT, a major genomics reagents supplier, challenged its validity, likely to remove a potential IP barrier to its multiplex PCR product lines. The Federal Circuit’s affirmance confirms the patent’s claims did not survive invalidity scrutiny.
An affirmance by the Federal Circuit means the court found no reversible legal or factual error in the lower tribunal’s decision. In a patentability context, it means the invalidity or cancellation determination stands. The patent claims are cancelled and unenforceable. The only remaining recourse for the patent holder is a petition for certiorari to the U.S. Supreme Court, which is rarely granted.
The cancellation of US10316359B2 removes one specific barrier in the multiplex PCR patent landscape, but does not guarantee broad FTO. Pillar Biosciences or other companies may hold continuation, divisional, or related patents covering overlapping methods. Companies should conduct a full patent family analysis and broader landscape review before relying on this cancellation for FTO purposes in clinical PCR or NGS workflows.
Case 22-2172 was filed on 1 September 2022 and decided on 20 December 2024, a duration of 841 days. This is consistent with substantively contested Federal Circuit appeals involving biotechnology patentability questions, where claim construction, prior art analysis, and written description challenges typically extend the appellate timeline beyond simpler procedural appeals.
PatSnap Eureka searches patents and litigation data to answer instantly.